VERTEX PHARMACEUTICALS INC / MA— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$3.19B
↑+9.5% +$278Mvs FY2024 (Q4)
Gross Profit
$2.72B
↑+9.5% +$235Mvs FY2024 (Q4)
Operating Income
$1.21B
↑+13.1% +$140Mvs FY2024 (Q4)
Net Income
$1.19B
↑+41.9% +$352Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $3.19B | $2.91B |
| COGS | $466M | $423M |
| Gross Profit | $2.72B | $2.49B |
| R&D | $974M | $999M |
| SG&A | $487M | $378M |
| D&A | $56M | $47M |
| Other OpEx | $2M | $0 |
| Operating Income | $1.21B | $1.07B |
| Interest Exp. | $3M | $3M |
| Other Non-Op | $0 | $0 |
| Pretax Income | $1.20B | $1.06B |
| Tax | $12M | $224M |
| Net Income | $1.19B | $840M |
QuarterCharts · SEC EDGAR data · VRTX · Comparing FY2025 (Q4) vs FY2024 (Q4)